CA2094608A1 - Construction d'adn pour fournir une therapie a l'arn - Google Patents

Construction d'adn pour fournir une therapie a l'arn

Info

Publication number: CA2094608A1
Authority: CA; Canada
Prior art keywords: rna; dna; dna construct; construct; segment
Prior art date: 1990-10-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002094608A

Other languages

English (en)

Inventor

John D. Taylor

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fox Chase Cancer Center

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-10-22

Filing date

1991-10-22

Publication date

1992-04-23

1991-10-22 Application filed by Individual filed Critical Individual

1992-04-23 Publication of CA2094608A1 publication Critical patent/CA2094608A1/fr

Status Abandoned legal-status Critical Current

Links

238000002560 therapeutic procedure Methods 0.000 title claims description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 90
108090000994 Catalytic RNA Proteins 0.000 claims abstract description 37
102000053642 Catalytic RNA Human genes 0.000 claims abstract description 37
108091092562 ribozyme Proteins 0.000 claims abstract description 37
230000001225 therapeutic effect Effects 0.000 claims abstract description 35
238000000034 method Methods 0.000 claims abstract description 18
108020005544 Antisense RNA Proteins 0.000 claims abstract description 13
241000700721 Hepatitis B virus Species 0.000 claims abstract description 8
239000000969 carrier Substances 0.000 claims abstract description 5
108020004414 DNA Proteins 0.000 claims description 81
208000037262 Hepatitis delta Diseases 0.000 claims description 53
241000724709 Hepatitis delta virus Species 0.000 claims description 53
210000004027 cell Anatomy 0.000 claims description 48
230000010076 replication Effects 0.000 claims description 26
239000003184 complementary RNA Substances 0.000 claims description 16
239000013598 vector Substances 0.000 claims description 16
241000894007 species Species 0.000 claims description 15
239000002773 nucleotide Substances 0.000 claims description 9
108020000999 Viral RNA Proteins 0.000 claims description 6
102000053602 DNA Human genes 0.000 claims description 5
241000700605 Viruses Species 0.000 claims description 5
108091092328 cellular RNA Proteins 0.000 claims description 5
125000003729 nucleotide group Chemical group 0.000 claims description 5
230000003362 replicative effect Effects 0.000 claims description 5
108020004394 Complementary RNA Proteins 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
241001084365 RNA satellites Species 0.000 claims description 3
210000004102 animal cell Anatomy 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
230000001580 bacterial effect Effects 0.000 claims 1
238000001415 gene therapy Methods 0.000 abstract description 5
208000015181 infectious disease Diseases 0.000 abstract description 3
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 12
239000002299 complementary DNA Substances 0.000 description 11
241000283923 Marmota monax Species 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
238000003780 insertion Methods 0.000 description 8
230000037431 insertion Effects 0.000 description 8
238000004458 analytical method Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
238000001890 transfection Methods 0.000 description 5
230000000295 complement effect Effects 0.000 description 4
208000002672 hepatitis B Diseases 0.000 description 4
210000003494 hepatocyte Anatomy 0.000 description 4
230000007017 scission Effects 0.000 description 4
210000002845 virion Anatomy 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
208000005331 Hepatitis D Diseases 0.000 description 3
101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
239000013638 trimer Substances 0.000 description 3
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
230000007022 RNA scission Effects 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
230000008520 organization Effects 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
HOBKVSAGFBYKRQ-VRWDCWMNSA-N 3-[[6-[3-carboxy-2,4,6-triiodo-5-(methylcarbamoyl)anilino]-6-oxohexanoyl]amino]-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)C1=C(I)C(C(=O)NC)=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C(=O)NC)C(I)=C(C(O)=O)C=2I)I)=C1I HOBKVSAGFBYKRQ-VRWDCWMNSA-N 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241001559589 Cullen Species 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000002494 Endoribonucleases Human genes 0.000 description 1
108010093099 Endoribonucleases Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
241000724007 Gloriosa stripe mosaic virus Species 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
108091030071 RNAI Proteins 0.000 description 1
108020005543 Satellite RNA Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
108091027544 Subgenomic mRNA Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
101150055766 cat gene Proteins 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
210000004777 protein coat Anatomy 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000472 rate-zonal centrifugation Methods 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000004513 sizing Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Virology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Plant Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Communicable Diseases (AREA)
Public Health (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Analytical Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA002094608A 1990-10-22 1991-10-22 Construction d'adn pour fournir une therapie a l'arn Abandoned CA2094608A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60213590A	1990-10-22	1990-10-22
US602,135		1990-10-22

Publications (1)

Publication Number	Publication Date
CA2094608A1 true CA2094608A1 (fr)	1992-04-23

Family

ID=24410108

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002094608A Abandoned CA2094608A1 (fr)	1990-10-22	1991-10-22	Construction d'adn pour fournir une therapie a l'arn

Country Status (5)

Country	Link
EP (1)	EP0554376A4 (fr)
JP (1)	JPH06502311A (fr)
AU (1)	AU662304B2 (fr)
CA (1)	CA2094608A1 (fr)
WO (1)	WO1992006693A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5948634A (en) *	1988-12-21	1999-09-07	The General Hospital Coporation	Neural thread protein gene expression and detection of alzheimer's disease
DE4203441C1 (de) *	1992-02-06	1993-10-14	Max Planck Gesellschaft	RNA- und DNA-Moleküle zur Erzeugung von Virusresistenzen
EP0642589A4 (fr) *	1992-05-11	1997-05-21	Ribozyme Pharm Inc	Procede et reactif d'inhibition de la replication virale.
US6469158B1 (en)	1992-05-14	2002-10-22	Ribozyme Pharmaceuticals, Incorporated	Synthesis, deprotection, analysis and purification of RNA and ribozymes
US6258585B1 (en)	1992-05-14	2001-07-10	Ribozyme Pharmaceuticals, Inc.	Method and reagent for inhibiting influenza virus replication
US6017756A (en) *	1992-05-14	2000-01-25	Ribozyme Pharmaceuticals, Inc.	Method and reagent for inhibiting hepatitis B virus replication
US5972699A (en)	1992-05-14	1999-10-26	Ribozyme Pharmaceuticals, Inc.	Method and reagent for inhibiting herpes simplex virus replication
US5610054A (en) *	1992-05-14	1997-03-11	Ribozyme Pharmaceuticals, Inc.	Enzymatic RNA molecule targeted against Hepatitis C virus
US5804683A (en) *	1992-05-14	1998-09-08	Ribozyme Pharmaceuticals, Inc.	Deprotection of RNA with alkylamine
US5891684A (en) *	1992-10-15	1999-04-06	Ribozyme Pharmaceuticals, Inc.	Base-modified enzymatic nucleic acid
JPH08508645A (ja) *	1993-04-05	1996-09-17	ユニバーシティオブコネティカット	アンチセンスポリリボヌクレオチドをコードする遺伝子の標的を定めた送達
AU7053894A (en) *	1993-06-09	1995-01-03	Ribozyme Pharmaceuticals, Inc.	Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease
EP0728199A1 (fr) *	1993-07-22	1996-08-28	Gene Shears Pty Limited	Ribozymes de virus a adn
US6015686A (en)	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
WO1995013378A1 (fr)	1993-11-08	1995-05-18	Ribozyme Pharmaceuticals, Inc.	Acide nucleique enzymatique a modification de base
CA2204355C (fr)	1994-11-02	2001-01-16	Gail Mandel	Canaux sodium specifiques du systeme nerveux peripherique, adn les codant, cristallisation, diffraction par les rayons x, modelisation moleculaire informatique, composition medicamenteuse rationnelle, criblage medicamenteux et procede de fabrication et d'utilisation de ces canaux
US5856459A (en) *	1995-06-06	1999-01-05	Hybridon, Inc.	Oligonucleotides specific for hepatitis B virus
US6451592B1 (en)	1996-04-05	2002-09-17	Chiron Corporation	Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP2298900A1 (fr)	1996-09-17	2011-03-23	Novartis Vaccines and Diagnostics, Inc.	Compositions et procédés de traitement de maladies intracellulaires
US7232899B2 (en)	1996-09-25	2007-06-19	The Scripps Research Institute	Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
JP3981416B2 (ja)	1997-04-10	2007-09-26	ユニバーシティメディカルセンターナイメーヘン	Ｐｃａ３タンパク質、ｐｃａ３遺伝子、及びこれらの用途
ATE376062T1 (de)	1997-08-04	2007-11-15	Cell Genesys Inc	Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
DE69933044T3 (de)	1998-11-27	2016-11-24	Ucb Pharma, S.A.	Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US7063850B1 (en)	1998-12-22	2006-06-20	University Of Tennessee Research Foundation	Protective antigen of group A Streptococci
US6911429B2 (en)	1999-04-01	2005-06-28	Transition Therapeutics Inc.	Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en)	1999-04-01	2005-03-08	Eva A. Turley	Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US8647864B2 (en)	1999-04-14	2014-02-11	Novartis Ag	Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
EP1950297A2 (fr)	2000-05-31	2008-07-30	Novartis Vaccines and Diagnostics, Inc.	Compositions et procédés de traitement de maladie néoplastique utilisant la chimiothérapie et des sensibilisateurs à rayonnement
DK1285080T3 (da)	2000-05-31	2008-12-01	Novartis Vaccines & Diagnostic	Fremgangsmåde til oprensning af alphavirusreplikonpartikler
US20020165192A1 (en)	2000-09-19	2002-11-07	Kerr William G.	Control of NK cell function and survival by modulation of ship activity
US7691821B2 (en)	2001-09-19	2010-04-06	University Of South Florida	Inhibition of SHIP to enhance stem cell harvest and transplantation
US7507542B2 (en)	2001-05-08	2009-03-24	Ucb Sa	Method for regulating immune function using the FOXP3 protein
WO2003065973A2 (fr)	2001-10-26	2003-08-14	Id Biomedical Corporation Of Washington	Compositions de vaccins multivalents a base de streptocoques et procedes d'utilisation
US7799523B2 (en)	2002-04-03	2010-09-21	Celltech R & D, Inc.	Association of polymorphisms in the SOST gene region with bone mineral density
CN1257284C (zh) *	2003-03-05	2006-05-24	北京博奥生物芯片有限责任公司	一种体外阻断乙肝病毒表达的方法
EP1636270B1 (fr)	2003-06-16	2016-07-20	UCB Pharma S.A.	Anticorps specifiques de la sclerostine et methodes permettant d'accroitre la mineralisation osseuse
US7807646B1 (en)	2003-11-20	2010-10-05	University Of South Florida	SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en)	2003-11-20	2010-07-27	University Of South Florida	SHIP-deficiency to increase megakaryocyte progenitor production
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
SMT202000095T1 (it)	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EP2681242B1 (fr)	2011-03-01	2018-01-24	Amgen Inc.	Agents liants bispécifiquement sclérostine et dkk-1
WO2012135035A1 (fr)	2011-03-25	2012-10-04	Amgen Inc.	Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
CA2842432C (fr)	2011-08-04	2022-10-04	Amgen Inc.	Procede de traitement de defauts d'espace osseux
SG11201403718YA (en)	2011-12-28	2014-07-30	Amgen Inc	Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
US9925260B2 (en)	2012-07-05	2018-03-27	Ucb Pharma S.A.	Treatment for bone diseases
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
EP3016660B1 (fr)	2013-07-01	2020-06-10	The Research Foundation for the State University of New York	Inhibition de ship dans le cadre de la lutte contre l'obésité
AU2015277194B2 (en)	2014-06-17	2020-10-22	The Research Foundation For The State University Of New York	Ship inhibition to induce activation of natural killer cells
MA41142A (fr)	2014-12-12	2017-10-17	Amgen Inc	Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en)	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
EP3774879B1 (fr)	2018-03-30	2026-01-28	Amgen Inc.	Variants d'anticorps anti-c-terminal

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4942125A (en) *	1984-09-07	1990-07-17	Scripps Clinic And Research Foundation	SV40 expression vector containing HBxAg as an expression marker
US5225347A (en) *	1989-09-25	1993-07-06	Innovir Laboratories, Inc.	Therapeutic ribozyme compositions and expression vectors

1991
- 1991-10-22 WO PCT/US1991/007859 patent/WO1992006693A1/fr not_active Ceased
- 1991-10-22 JP JP4500794A patent/JPH06502311A/ja active Pending
- 1991-10-22 AU AU89575/91A patent/AU662304B2/en not_active Ceased
- 1991-10-22 EP EP9191920437A patent/EP0554376A4/en not_active Withdrawn
- 1991-10-22 CA CA002094608A patent/CA2094608A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
AU8957591A (en)	1992-05-20
AU662304B2 (en)	1995-08-31
EP0554376A4 (en)	1994-08-24
EP0554376A1 (fr)	1993-08-11
JPH06502311A (ja)	1994-03-17
WO1992006693A1 (fr)	1992-04-30

Legal Events

Date	Code	Title	Description
1997-10-22	FZDE	Dead

Publication	Publication Date	Title
AU662304B2 (en)	1995-08-31	DNA construct for providing RNA therapy
US5225347A (en)	1993-07-06	Therapeutic ribozyme compositions and expression vectors
JP4062365B2 (ja)	2008-03-19	短い外部ガイド配列
AU702373B2 (en)	1999-02-18	Stabilized external guide sequences
Christoffersen et al.	1995	Ribozymes as human therapeutic agents
US6107028A (en)	2000-08-22	Ribozymes for treating hepatitis C
Casey	2011	Control of ADAR1 editing of hepatitis delta virus RNAs
US5610050A (en)	1997-03-11	Methods of preventing viral replication
JP2000506010A (ja)	2000-05-23	Ｃ型肝炎ウイルスリボザイム
US20040054156A1 (en)	2004-03-18	Method and reagent for inhibiting hepatitis B viral replication
Wang et al.	1997	Identification of the functional regions required for hepatitis D virus replication and transcription by linker-scanning mutagenesis of viral genome
US20030068301A1 (en)	2003-04-10	Method and reagent for inhibiting hepatitis B virus replication
Hsieh et al.	1992	Delta virus as a vector for the delivery of biologically-active RNAs: possibly a ribozyme specific for chronic hepatitis B virus infection
JPH09507062A (ja)	1997-07-15	抗ｂ型肝炎ウイルスオリゴヌクレオチド
Elkins et al.	2017	Cellular delivery of ribozymes
Strauss	1997	Antisense molecules and ribozymes: medical application
MAEDA et al.	1994	Inhibition of viral multiplication by hammerhead ribozymes targeted against the polymerase gene of mouse hepatitis virus
WO2003093473A1 (fr)	2003-11-13	Construction de ribozyme multimère auto-clivant
Weinberg	2002	Inhibiting Hepatitis B Virus Gene Expression with Hammerhead Ribozymes that Target the HBx Open Reading Frame
Netter et al.	1995	Hepatitis delta virus
EP1015617A4 (fr)	2001-05-09	Vecteurs viraux sv40 destines a une integration ciblee dans des cellules
WO1998048842A1 (fr)	1998-11-05	Utilisation d'un baculovirus modifie contenant un acide nucleique exogene pour preparer un medicament servant a administrer ledit acide nucleique aux hepatocytes
Kijima et al.	1997	Cancer Gene Therapy
ZA200408825B (en)	2005-07-05	A multimeric self-cleaving ribozyme construct.
WO2000014252A1 (fr)	2000-03-16	Ribozyme promedicament